Modified Shenlingbaizhu decoction suppresses colon cancer via enhancing memory-like Tfh differentiation and B cell responses - PubMed
3 hours ago
- #traditional medicine
- #colon cancer
- #immune response
- Modified Shenlingbaizhu decoction (MSD) enhances anti-tumor immunity in microsatellite stable (MSS) colorectal cancer.
- MSD increases memory-like follicular helper T cells (Tfh) and B cells in colon adenocarcinoma (COAD) tumors.
- Single-cell RNA sequencing (scRNA-seq) shows MSD enhances secretion of CCL20 and CXCL13.
- CCL20 neutralization impairs MSD's effects on B cell migration and tumor-associated aggregates (TAAs) formation.
- B cell depletion reduces memory-like Tfh cells and their stemness, weakening MSD's therapeutic efficacy.
- Memory-like Tfh cells rapidly transition to effector state during secondary immune responses, boosting B cell differentiation and IgG secretion.
- MSD upregulates Jarid2 in Tfh cells; Jarid2 knockdown reduces memory-like Tfh cells and ICOS receptor expression.
- Mutual interaction between B cells and memory-like Tfh cells is key for MSS COAD treatment.
- MSD promotes TAA formation to enhance Tfh/B cell collaboration via CCL20.